Literature DB >> 34521099

Ibrutinib induces durable remissions in treatment-naïve patients with CLL and 17p deletion and/or TP53 mutations.

Mariela Sivina1, Ekaterina Kim1, William G Wierda1, Alessandra Ferrajoli1, Nitin Jain1, Philip Thompson1, Hagop Kantarjian1, Michael Keating1, Jan A Burger1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34521099      PMCID: PMC8832441          DOI: 10.1182/blood.2021012315

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

1.  Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.

Authors:  Kirsten Fischer; Jasmin Bahlo; Anna Maria Fink; Valentin Goede; Carmen Diana Herling; Paula Cramer; Petra Langerbeins; Julia von Tresckow; Anja Engelke; Christian Maurer; Gabor Kovacs; Marco Herling; Eugen Tausch; Karl-Anton Kreuzer; Barbara Eichhorst; Sebastian Böttcher; John F Seymour; Paolo Ghia; Paula Marlton; Michael Kneba; Clemens-Martin Wendtner; Hartmut Döhner; Stephan Stilgenbauer; Michael Hallek
Journal:  Blood       Date:  2015-10-20       Impact factor: 22.113

2.  Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.

Authors:  Jennifer A Woyach; Amy S Ruppert; Nyla A Heerema; Weiqiang Zhao; Allison M Booth; Wei Ding; Nancy L Bartlett; Danielle M Brander; Paul M Barr; Kerry A Rogers; Sameer A Parikh; Steven Coutre; Arti Hurria; Jennifer R Brown; Gerard Lozanski; James S Blachly; Hatice G Ozer; Brittny Major-Elechi; Briant Fruth; Sreenivasa Nattam; Richard A Larson; Harry Erba; Mark Litzow; Carolyn Owen; Charles Kuzma; Jeremy S Abramson; Richard F Little; Scott E Smith; Richard M Stone; Sumithra J Mandrekar; John C Byrd
Journal:  N Engl J Med       Date:  2018-12-01       Impact factor: 91.245

3.  Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.

Authors:  Tait D Shanafelt; Xin V Wang; Neil E Kay; Curtis A Hanson; Susan O'Brien; Jacqueline Barrientos; Diane F Jelinek; Esteban Braggio; Jose F Leis; Cong C Zhang; Steven E Coutre; Paul M Barr; Amanda F Cashen; Anthony R Mato; Avina K Singh; Michael P Mullane; Richard F Little; Harry Erba; Richard M Stone; Mark Litzow; Martin Tallman
Journal:  N Engl J Med       Date:  2019-08-01       Impact factor: 91.245

4.  Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia.

Authors:  Jan A Burger; Mariela Sivina; Nitin Jain; Ekaterina Kim; Tapan Kadia; Zeev Estrov; Graciela M Nogueras-Gonzalez; Xuelin Huang; Jeffrey Jorgensen; Jianling Li; Mei Cheng; Fong Clow; Maro Ohanian; Michael Andreeff; Thomas Mathew; Philip Thompson; Hagop Kantarjian; Susan O'Brien; William G Wierda; Alessandra Ferrajoli; Michael J Keating
Journal:  Blood       Date:  2018-12-07       Impact factor: 22.113

5.  Ibrutinib for Chronic Lymphocytic Leukemia with TP53 Alterations.

Authors:  Inhye E Ahn; Xin Tian; Adrian Wiestner
Journal:  N Engl J Med       Date:  2020-07-30       Impact factor: 91.245

Review 6.  Treatment of Chronic Lymphocytic Leukemia.

Authors:  Jan A Burger
Journal:  N Engl J Med       Date:  2020-07-30       Impact factor: 91.245

7.  Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.

Authors:  John C Byrd; Richard R Furman; Steven E Coutre; Ian W Flinn; Jan A Burger; Kristie Blum; Jeff P Sharman; William Wierda; Weiqiang Zhao; Nyla A Heerema; Ying Luan; Emily A Liu; James P Dean; Susan O'Brien
Journal:  Clin Cancer Res       Date:  2020-03-24       Impact factor: 12.531

8.  Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study.

Authors:  Jan A Burger; Paul M Barr; Tadeusz Robak; Carolyn Owen; Paolo Ghia; Alessandra Tedeschi; Osnat Bairey; Peter Hillmen; Steven E Coutre; Stephen Devereux; Sebastian Grosicki; Helen McCarthy; David Simpson; Fritz Offner; Carol Moreno; Sandra Dai; Indu Lal; James P Dean; Thomas J Kipps
Journal:  Leukemia       Date:  2019-10-18       Impact factor: 11.528

9.  Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study.

Authors:  Arnon P Kater; Jenny Qun Wu; Thomas Kipps; Barbara Eichhorst; Peter Hillmen; James D'Rozario; Sarit Assouline; Carolyn Owen; Tadeusz Robak; Javier de la Serna; Ulrich Jaeger; Guillaume Cartron; Marco Montillo; Julie Dubois; Eric Eldering; Clemens Mellink; Anne-Marie Van Der Kevie-Kersemaekers; Su Young Kim; Brenda Chyla; Elizabeth Punnoose; Christopher R Bolen; Zoe June Assaf; Yanwen Jiang; Jue Wang; Marcus Lefebure; Michelle Boyer; Kathryn Humphrey; John F Seymour
Journal:  J Clin Oncol       Date:  2020-09-28       Impact factor: 44.544

  10 in total
  4 in total

1.  TP53-altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor-based therapy: A retrospective analysis.

Authors:  Hua-Jay J Cherng; Raamis Khwaja; Rashmi Kanagal-Shamanna; Guilin Tang; Jan Burger; Philip Thompson; Alessandra Ferrajoli; Zeev Estrov; Koji Sasaki; Deepa Sampath; Xuemei Wang; Hagop Kantarjian; Michael Keating; William G Wierda; Nitin Jain
Journal:  Am J Hematol       Date:  2022-05-30       Impact factor: 13.265

2.  Is BTKi or BCL2i preferable as first novel therapy in patients with CLL? The case for BCL2i.

Authors:  John F Seymour
Journal:  Blood Adv       Date:  2022-02-22

3.  [72/m with an incidental finding of lymphocytosis].

Authors:  Petra Langerbeins; Barbara Eichhorst; Michael Hallek
Journal:  Onkologe (Berl)       Date:  2022-04-13       Impact factor: 0.170

Review 4.  Selecting the optimal BTK inhibitor therapy in CLL: rationale and practical considerations.

Authors:  Alexandra R Lovell; Nadya Jammal; Prithviraj Bose
Journal:  Ther Adv Hematol       Date:  2022-08-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.